Skip Navigation
Skip to contents

PHRP : Osong Public Health and Research Perspectives



Page Path
HOME > Osong Public Health Res Perspect > Volume 13(1); 2022 > Article
Review Article
Points to consider for COVID-19 vaccine quality control and national lot release in Republic of Korea: focus on a viral vector platform
Jung Hun Ju1orcid, Naery Lee1orcid, Sun-hee Kim1orcid, Seokkee Chang1orcid, Misook Yang1orcid, Jihyun Shin1orcid, Eunjo Lee1orcid, Sunhwa Sung1orcid, Jung-Hwan Kim1orcid, Jin Tae Hong2orcid, Ho Jung Oh1orcid
Osong Public Health and Research Perspectives 2022;13(1):4-14.
Published online: February 8, 2022

1Emerging Infectious Disease Vaccines Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, Cheongju, Korea

2College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Korea

Corresponding author: Ho Jung Oh Emerging Infectious Disease Vaccines Division, National Institute of Food and Drug Safety Evaluation, Ministry of Food and Drug Safety, 187 Osongsaengmyeong 2-ro, Osong-eup, Heungdeok-gu, Cheongju 28159, Korea E-mail:
• Received: November 17, 2021   • Revised: December 7, 2021   • Accepted: December 30, 2021

© 2022 Korea Disease Control and Prevention Agency.

This is an open access article under the CC BY-NC-ND license (

  • 177 Download
  • 1 Scopus
  • Due to the global public health crisis caused by the coronavirus disease 2019 (COVID-19) pandemic, the importance of vaccine development has increased. In particular, a rapid supply of vaccines and prompt deployment of vaccination programs are essential to prevent and overcome the spread of COVID-19. As a part of the vaccine regulations, national lot release is regulated by the responsible authorities, and this process involves the assessment of the lot before a vaccine is marketed. A lot can be released for use when both summary protocol (SP) review and quality control testing are complete. Accelerated lot release is required to distribute COVID-19 vaccines in a timely manner. In order to expedite the process by simultaneously undertaking the verification of quality assessment and application for approval, it is necessary to prepare the test methods before marketing authorization. With the prolonged pandemic and controversies regarding the effectiveness of the COVID-19 vaccine against new variants, public interest for the development of a new vaccine are increasing. Domestic developers have raised the need to establish standard guidance on the requirements for developing COVID-19 vaccine. This paper presents considerations for quality control in the manufacturing process, test items, and SP content of viral vector vaccines.
A common issue currently facing countries throughout the world is how to return to pre-coronavirus disease 2019 (COVID-19) daily life when the COVID-19 pandemic ends. COVID-19 is a respiratory syndrome caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which first emerged in Wuhan, Hubei Province, China in December 2019. In the absence of specific therapeutics or vaccines to prevent this new infectious disease, it has spread all over the world. Accordingly, the World Health Organization (WHO) declared the COVID-19 outbreak as a public health emergency of international concern on January 30, 2020. The WHO then made the assessment that COVID-19 could be characterized as a pandemic. At that time, about 120,000 people in 110 countries were infected with the virus [1,2].
In the exceptional situation of a pandemic, the pharmaceutical industry, regulatory authorities, governments, and international organizations have coordinated collaborative strategies, and many national regulatory authorities have eased regulations to accelerate the development of COVID-19 vaccines. In order to facilitate access to COVID-19 vaccines, regulatory authorities have executed innovative and agile regulatory measures such as conditional marketing authorizations or emergency use authorizations. These measures are intended to ensure that patients could be supplied with COVID-19 therapeutics or vaccines as quickly as possible. These new regulatory applications involve expedited regulatory reviews for COVID-19 vaccines without compromising their safety, effectiveness, and quality [38]. As a result, the vaccine development process, which normally takes about 10 years, has been shortened to within about 1 year, from development to review and approval, and then to vaccination. Tables 1 and 2 show the authorization and approval status of COVID-19 vaccines by stringent regulatory authorities. In the Republic of Korea, the AstraZeneca vaccine, a viral vector platform vaccine was first authorized on February 10, 2021, followed by the Pfizer-BioNTech vaccine, Janssen vaccine, and Moderna vaccine, which have been approved and used [9].
In the Republic of Korea, it is stipulated that vaccines shall obtain lot release approval from the Ministry of Food and Drug Safety (MFDS) after undergoing the examination and verification of the data on manufacturing and quality management in accordance with the Pharmaceutical Affairs Act, Article 53. For biologics such as vaccines, reviews have been implemented to further confirm the quality of each lot of the product before its release onto the market. A national lot release system has been implemented to review the summary protocol (SP) for its production and quality control tests. The SP refers to a summarized document regarding the manufacturing process and test results of a product, ranging from raw materials to the final product (Figure 1). When the MFDS receives the application for a national lot release, the applicant is notified of the result after lot release testing and a review of the data concerning the product’s manufacturing and quality control. If the criteria are satisfied, a certificate of approval for the national lot release shall be issued [10]. Normally, the applicant is notified of the specifications and test methods of products for lot release, and then the subsequent lot release process is carried out after marketing authorization. However, as COVID-19 vaccines were designated as crisis-response medical products (specifically, as preventive vaccines for a pandemic infectious disease), they are subject to expedited national lot release. The MFDS has prioritized COVID-19 vaccines over other lot releases, and rapidly verified the quality of the vaccines [11]. The MFDS has committed to the improvement of the national quality control system for biologics and established a comprehensive lot release system. The National Institute of Food and Drug Safety Evaluation (NIFDS), an affiliated organization of the MFDS, is responsible for this task.
To push ahead with the lot release further, simultaneous applications for marketing authorization and lot release have been conducted. The MFDS reviewed the safety and quality verification methods prior to the drug approval process of COVID-19 vaccines, and established the test methods before the application for lot release. Necessary equipment and instruments were also prepared. MFDS expedited the lot release process, which generally takes 2 or 3 months, and approved the lot release within 20 days. By the third quarter of 2021, the MFDS has approved the national lot release of 67.64 million doses (for domestic use) of COVID-19 vaccines. As of November 2021, 87.05 million doses—an amount with which more than 44 million people can be fully vaccinated—were approved for lot release. Thus, it became feasible to swiftly provide the necessary quantity of vaccines in a timely manner amid the spread of COVID-19. The status of domestic COVID-19 vaccine lot release and product information is available from the MFDS website ( and the integrated drug information system (, respectively.
Vaccine manufacturing technology has been continuously developed as a solution to prevent infectious diseases. A vaccine platform refers to a technology for vaccine development by changing specific antigens or genetic information. A single vaccine platform commonly addresses a specific pathogen. However, the COVID-19 pandemic yielded a competitive situation, wherein various platforms were used to develop new vaccines with the goal of rapidly obtaining an effective vaccine. Currently, COVID-19 vaccine platform modalities include inactivated virus vaccines, attenuated virus vaccines, recombinant viral vector vaccines, recombinant subunit vaccines, DNA vaccines, and RNA vaccines [12,13]. As of December 3, 2021, there are 135 candidates in the clinical phase of development, of which vaccines using protein subunits accounted for 34.8% (n=47), RNA vaccines accounted for 15.6% (n=21), and viral vectors (non-replicating) accounted for 14.8% (n=20) (Table 3) [14].
Since the manufacturing technology and quality control processes required for each platform are novel and unique, the establishment of test methods is time-consuming. Furthermore, each vaccine platform has advantages and drawbacks, including differences in production, efficacy, safety profile, and immune response. Therefore, it is essential to recognize the characteristics of every vaccine candidate and the specific quality considerations for each platform [12]. If new technology platform development guidelines are provided for use in quality control and testing, the vaccine development timeline could be significantly shortened. Accordingly, the NIFDS published 2 national lot release guidelines for new technology platforms for COVID-19 vaccines (viral vector vaccines and mRNA vaccines) by referring to the approval and review data of COVID-19 vaccines by the MFDS, WHO, and European Medicines Quality Committee (EDQM) guidelines [15,16].
Viral vector vaccines are defined as live viruses that are genetically engineered to express 1 or more heterologous antigens [17]. Recombinant viral vector vaccines are generated by cloning the gene for an antigen from the pathogen into an avirulent host such as an adenovirus. Viral vector vaccines enter cells and produce the vaccine antigen, stimulating an immune response. Developing a recombinant viral vector vaccine that mimics a pathogen (e.g., SARS-CoV-2), which is the cause of the COVID-19 pandemic, but is not virulent, is known to be a safe option [12,13]. Several recombinant viral vectors derived from other viruses have emerged as gene delivery systems [18]. In particular, adenoviruses were initially characterized and have been used as gene delivery vectors since the early stages of gene therapy. Adenoviral vectors have been explored as vaccine agents for infectious diseases. Thus, as logical vaccine candidates, adenoviral vector vaccines are expected to be useful as a response to the COVID-19 pandemic as they are known to induce a potent and balanced immune response [19]. Two viral vector vaccines are currently commercialized in Republic of Korea. These vaccines contain adenovirus engineered to carry a SARS-CoV-2 gene, using a chimpanzee-derived adenovirus (AstraZeneca vaccine) or a human-derived adenovirus (Janssen vaccine) vector as a delivery system.
In this paper, we describe considerations for the management of COVID-19 viral vector vaccines under the regulatory system in the Republic of Korea, with a particular focus on specific lot release tests and information to be included in the SP. This paper is intended to provide an internationally harmonized guideline by comparing and reviewing the EDQM document for recombinant viral vector vaccines [17], the WHO and Official Control Authority Batch Release (OCABR) guidelines [2023], and the United States Pharmacopoeia (USP) COVID-19 vaccine quality assessment toolkits [24].
The quality control tests that can be performed at each stage of manufacturing a viral vector-based COVID-19 vaccine are as follows. This document is expected to help COVID-19 vaccine developers prepare an appropriate analytical strategy during vaccine development. Additional tests may be considered on a case-by-case basis, depending on the characteristics of the vector backbone and the specific manufacturing process established.
Cell Substrates for Viral Vector Propagation
The vector can be propagated in human diploid cell lines, continuous cell lines, chick-embryo cells, or in the amniotic membrane of chick embryos derived from specific pathogen-free chickens [17]. More specific test information on human diploid cells and immortal cell lines used as cell substrates for the propagation of recombinant viral vectors can be obtained from the MFDS guidelines [25,26] and European Pharmacopoeia Chapter 5.2.3 [27]. The cell substrates need to be used with a cell banking system.
The most widely used method of viral vector development involves homologous recombination [28]. Certain replication-defective viral vectors may require testing for replication-competent viruses. Replication-competent viral vectors may incur significant issues with quality control when there is a wide homology region between the viral genome and the genome of the complementation cell. This expression could reduce the replication capacity by minimizing the homology between both genomes. It is recommended to use cells without homology between the vector and sequence for production.
Viral Vector Seed Lot
Recombinant viral vector production generally uses a seed lot system (master virus strain and working virus strain). The number of passages is controlled based on evidence regarding the maximum number of passages, and production cannot exceed the maximum passage level. Historical records, including information on the strain origin of the viral vector used for vaccine production, and in particular, subsequent manipulation of deleted or modified regions, should be confirmed. Genetic insert and flanking control regions should be described in detail, including the nucleotide sequences. The origin of genetic inserts into the vectors and the engineering methods should be documented. A relevant characterization could be carried out based on the nature of the viral vector and the results of pre-clinical studies.
Propagation and Harvest
It is preferable to produce vectors without the use of antibiotics. Penicillin or streptomycin should not be used at any stage of manufacture if insufficient data support doing so. It is necessary to provide information on control cell culture. A single harvest refers to the biological material prepared from a single production run.
A bulk refers to the one containing active ingredient prior to formulation. The purification process could be applied to a pool of single harvests. The purification process should be validated for removal of impurities. The following test items may be considered for controlling the bulk: identification, vector concentration, infectious vector titer, ratio of vector particle concentration to infectious vector titer, ratio of infectious vector titer to total protein concentration, transgene expression, host-cell protein, host-cell DNA, vector aggregation, residual reagents, residual antibiotics, the absence of replication-competent viral vectors, microbial control (microbial limit or sterility), and endotoxin.
Final Bulk
The final bulk may consist of 1 or more bulks. In preparing the final bulk, any excipients such as stabilizers are added to the product. The following tests could be considered for control of the final bulk: microbial control (microbial limit or sterility) and preservative.
Final Product
Control tests for the final product are shown in Table 4. If a test for bovine serum albumin or ovalbumin (if applicable) has been carried out on the bulk or the final bulk, they may be omitted on the final product.
Test Items and Methods
Regulatory authorities in the countries such as the United States, Europe, and Japan are supporting the development of COVID-19 vaccines by providing guidance, quality standards, and training materials to vaccine developers and manufacturers [2024]. In the context of the COVID-19 pandemic, the EDQM published the first analytical strategy options on the quality control of COVID-19 recombinant viral vector vaccines in November 2020. In this document, the mandatory tests at each stage of viral vector vaccine manufacturing (from raw materials to the final product) are presented [20]. The USP provided a toolkit for the quality evaluation items and test methods for each COVID-19 vaccine platform (mRNA vaccine, inactivated vaccine, and viral vector vaccine) in July 2021 [24]. Japan registered a monograph of test items and standards for domestically authorized COVID-19 vaccines (Pfizer-BioNTech, Moderna, and AstraZeneca) in the Minimum Requirements for Biological Products (MRBP) [22]. The NIFDS published a Guideline on National Lot Release for COVID-19 Viral Vector Vaccines [15], and SARS-CoV-2 viral vector vaccines fee for national lot release was added to the Regulation on Fees for Pharmaceutical Approval, etc. on October 21, 2021 [29]. In addition, in order to ensure the transparency and clarify of the lot release system, revisions of the Regulation for Designation, Approval Process, and Method of Pharmaceuticals for National Lot Release, which describes the amount of samples and test items for newly authorized COVID-19 vaccines, are in progress, and the proposed amendment will be announced within this year.
The test items, objectives, and possible methods in Table 4 are necessary information to be considered in the quality control of the final product, but they are not set criteria for lot release. Generally, test specifications and methods subject to lot release should be in compliance with the MRBP (NFDS Notification). However, the Minister of the MFDS may adjust them partially considering the characteristics of the product according to the approved Specification and Analytical Procedures.
National Lot Release Tests
Specifications and test methods include product-specific tests such as identification, purity, potency, and tests for preservatives and stabilizers used in manufacturing. Further, sterility and endotoxin tests are conducted to confirm product safety. In addition, in accordance with the MRBP (MFDS Notification), the details of the necessary criteria such as the nature, condition, and quality of vaccines could be determined. Table 5 demonstrates the recommended test items and methods for viral vector vaccines. The test items performed for the national lot release of viral vector vaccines (AstraZeneca and Janssen vaccines) authorized in Korea are as follows. The lot release test items of AstraZeneca vaccine include appearance, pH, sterility, endotoxin, identity, potency (infectivity), virus particle concentration, purity (ratio of DNA to protein, ratio of virus particle to infectious virus), and container content for injections. The test items for Janssen vaccine lot release include appearance, pH, sterility, endotoxin, identity (virus identity, virus protein identity), potency (transgene expression, infectious titer, and ratio of virus particle to infectious virus), concentration, purity, and container content for injections. The test items for both vaccines are included in the revised content of the Regulation for Designation, Approval Process, and Method of Pharmaceuticals for National Lot Release.
Table 6 shows the test items for COVID-19 viral vector vaccines tested by the National Regulatory Authority and National Control Laboratory. The test items performed by the European Network of Official Medicines Control Laboratories are specified in the OCABR guideline [21], and the Australian government provides guidance on the assessment items for COVID-19 vaccine batch release through the Therapeutic Goods Administration website [23].
SP Review
The manufacturer’s SP is the summarized information taken from the manufacturing and testing results according to Good Manufacturing Practice requirements to ensure that the lot meets the specifications of the marketing authorization. The SP contains data on all appropriate production steps and controls, and it is certified and signed by the person in charge of the manufacturing company [30].
As shown in Table 7, information on the production and storage at each stage of the manufacturing process, including information on the passage history of cell strains/virus strains used as raw materials, as well as the test methods, specifications, and results should be provided in the SP. For reference, an SP template is included with the Guideline on National Lot Release for COVID-19 Viral Vector Vaccines [15]. The manufacturer or importer will be notified of the SP form. However, it is thus possible that SP for a specific product may differ in detail from the provided model.
The still ongoing COVID-19 pandemic demands a global response due to the occurrence and spread of variants with novel mutations. Around the world, people are looking for explicit scientific evidence and useful guidance to deal with this unprecedented pandemic. The currently predominating Delta variant lowers the effectiveness of vaccination, leading to the 4th wave of the epidemic [31]. The Delta variant is eightfold less sensitive to ChAdOx1 vaccine-elicited antibodies than the wild-type Wuhan-1. It was also confirmed that the neutralizing antibodies from those who had recovered or been vaccinated showed decreased effectiveness against the Delta variant [32]. Although the current vaccines could reduce the hospitalization and mortality rate, it is also necessary to develop a next-generation vaccine to cope with breakthrough infections. Vaccination is recognized as the best game-changer that mitigates the current pandemic [33], considering its superior effectiveness and capability as a safe public health intervention to prevent infections. Therefore, the rapid production and supply of safe and effective vaccines to protect people and mitigate the economic and social impacts of infectious diseases should be prioritized [34,35].
In the middle of the 20th century, vaccine production technology made substantial advances as vaccines were produced by virus propagation in cell culture. Through these technological innovations, vaccine development platforms have been diversified [12]. Historically, 4 classic platforms (inactivated virus, live-attenuated virus, protein subunit, and virus-like particle) constituted most vaccine products [13]. However, in response to COVID-19, developers are looking for more up-to-date technologies in order to avoid the safety and efficacy concerns associated with traditional platforms targeting SARS-CoV-2 [12]. The currently commercialized COVID-19 vaccines were developed quickly, even though they were based on recent technologies. The reasons for the success of vaccine development with a rapid timeline are as follows: SARS-CoV-2 is closely related to SARS-CoV, and through the accumulated data on SARS-CoV and Middle East respiratory syndrome coronavirus, a spike protein has been identified as the antigenic target for coronavirus vaccines [36,37]. This enabled the more rapid design and development of SARS-CoV-2 vaccine candidates after the emergence of this new virus, as well as sharing the SARS-CoV-2 gene sequence, diversifying vaccine development strategies, supporting development costs, and shortening the period from vaccine approval to distribution by expediting the regulatory response system to COVID-19. In other words, the rapid development and deployment of COVID-19 vaccines resulted from organically harmonized efforts and collaboration to manage this public health crisis.
One of the hurdles regarding COVID-19 vaccine development is how to decide upon the most appropriate platform to target SARS-CoV-2. It has not been determined which kind of platform would be the most effective against the novel coronavirus. Therefore, all vaccine platforms are being explored as COVID-19 vaccine candidates. Inactivated, attenuated, and recombinant vaccines using pathogens or antigenic proteins have been successful for targeting other infectious diseases. Novel platforms such as viral vector vaccines or nucleic acid vaccines have not been sufficiently used to fully establish their safety and efficacy in humans, but these platforms have been used worldwide as major vaccines for COVID-19. There are 135 candidates in the clinical development stage, of which viral vector vaccines and nucleic acid vaccines account for about 43.0% (36 nucleic acid platforms and 22 viral vector platforms) as of December 3, 2021 (Table 3).
Unlike chemically synthesized pharmaceuticals, vaccines are manufactured from biological sources. They should be produced consistently and show comparability from lot to lot, demonstrating clinical efficacy, immunogenicity, and safety. Furthermore, since vaccines are biological products with a complex nature and inherent potential for variability, it is difficult to produce vaccines with consistency, safety, and effectiveness even under similar manufacturing conditions. Therefore, an independent review of manufacturing and quality control data from each vaccine lot is essential to assure the consistent quality of manufactured lots [30]. Reliable and authorized guidance needs to provide support through regulatory requirements for quality management. Since the outbreak of the COVID-19 pandemic, regulatory agencies such as the WHO, Europe, United States, and Japan have provided high-quality documents in order to support COVID-19 vaccine developers currently working on candidate vaccines based on recent technologies, such as nucleic acid vaccines and recombinant viral vector vaccines. The Republic of Korea has published lot release guidelines on COVID-19 vaccine platforms (viral vector vaccines, mRNA vaccines) to harmonize the global regulatory requirements for lot release and to accelerate vaccine development [15,16].
This paper is intended to serve as guidance for regulatory systems dealing with the lot release. Furthermore, this paper also provides general considerations for quality control and tests applicable to vaccine development and quality evaluation using the viral vector platform. Lot release test items and methods provided are prepared based on drug approval and review cases, and national lot release cases for domestically approved replication-defective adenoviral vector vaccines. This information will help vaccine developers to minimize industry trials and expedite commercialization by providing predictable regulatory requirements for the same platform vaccine. However, it should be noted that quality control items and considerations may be different depending on the replication-competent viral vector and/or the nature of the vector backbone as the vaccine delivery system. The quality tests provided herein have been drawn up using available knowledge to date, and the content may be updated as needed to change the regulatory system and/or to reflect further experience gained with new products. Emerging infectious disease disasters such as the COVID-19 pandemic are expected to occur periodically. In order to accelerate vaccine development for novel infectious diseases such as COVID-19, technical support for globally harmonized quality requirements is urgently needed.

Ethics Approval

Not applicable.

Conflicts of Interest

The authors have no conflicts of interest to declare.



Availability of Data

All data generated or analyzed during this study are included in this published article. Other data may be requested from the corresponding author.

Authors’ Contributions

Conceptualization: JHJ, JTH; Data curation: NL, SHK, SC, MY, JS, EL, SS, JHK; Writing-original draft: JHJ, NL, HJO; Writing-review & editing: JTH, HJO.

Figure 1.
National lot release system in the Republic of Korea.
Table 1.
Authorization and approval status of COVID-19 vaccines (overseas: ICH founding & standing regulatory members)
Platform Viral vector vaccines
mRNA vaccines
ChAdOx1-SARS-CoV-2 vaccine
Ad26.COV2.S vaccine
Developer AstraZeneca/Oxford
Product information Name Approval/date Name Approval/date Name Approval/date Name Approval/date
 United States, FDA - - COVID-19 vaccine Janssen EUA/February 27, 2021 Comirnaty (COVID-19 vaccine, mRNA) MA/August 23, 2021 (EUA/December 11, 2020) Moderna COVID-19 vaccine EUA/December 18, 2020
 EC, EMA Vaxzevria (previously AstraZeneca COVID-19 vaccine) CMA/January 29, 2021 COVID-19 vaccine Janssen CMA/March 11, 2021 Comirnaty CMA/December 21, 2020 Spikevax (previously Moderna COVID-19 vaccine) CMA/January 6, 2021
 Japan, MHLW/PMDA Vaxzevria SAFE/May 21, 2021 - - Comirnaty SAFE/February 14, 2021 COVID-19 Moderna SAFE/May 21, 2021
 Canada, HC Vaxzevira COVID-19 vaccine ISAD IO/February 26, 2021 Janssen (Johnson & Johnson) COVID-19 vaccine ISAD IO/March 5, 2021 Comirnaty COVID-19 vaccine MA/September 16, 2021 (ISAD IO/December 9, 2020) Spikevax COVID-19 vaccine MA/September 16, 2021 (ISAD IO/December 23, 2020)
 Switzerland, Swissmedic - - Janssen COVID-19 vaccine TPA/March 22, 2021 Comirnaty TPA/December 19, 2020 Spikevax TPA/January 12, 2021

Available from regulatory authority websites as of October 2021 (sources: FDA,; EMA,; PMDA,; Health Canada,; Swissmedic,

COVID-19, coronavirus disease 2019; ICH, International Council for Harmonization; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; FDA, Food and Drug Administration; MA, marketing authorization; EUA, emergency use authorization; EC, European Commission; CMA, conditional marketing authorization; MHLW, Ministry of Health, Labour and Welfare; PMDA, Pharmaceuticals and Medical Devices Agency; SAFE, special approval for emergency; HC, Health Canada; ISAD IO, interim order pathway for COVID-19-related drugs and vaccines; TPA, temporary authorization; -, unauthorized or unapproved.

Table 2.
Authorization and approval status of COVID-19 vaccines (domestic)
No. License holder Product Approval date (manufacture/import) Platform
1 AstraZeneca Korea Co. Ltd. Vaxzevria injection COVID-19 vaccine (SARS-CoV-2 viral vector vaccine) February 10, 2021 (manufacture) Viral vector vaccine
May 21, 2021(import)
2 Pfizer Pharmaceuticals Korea Ltd. Comirnaty injection (tozinameran) (SARS-CoV-2 mRNA vaccine) March 5, 2021 (import) mRNA vaccine
3 Janssen Korea Ltd. COVID-19 vaccine Janssen injection (SARS-CoV-2 viral vector vaccine) April 7, 2021 (import) Viral vector vaccine
4 Green Cross Corp. Moderna Spikevax injection (SARS-CoV-2 mRNA vaccine) May 21, 2021 (import) mRNA vaccine

COVID-19, coronavirus disease 2019; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

Available from Ministry of Food and Drug Safety website (source:

Table 3.
Global COVID-19 vaccine candidates in clinical development (n=135)
Platform n (%)
Protein subunit 47 (34.8)
Viral vector (non-replicating) 20 (14.8)
DNA 15 (11.1)
Inactivated virus 18 (13.3)
RNA 21 (15.6)
Viral vector (replicating) 2 (1.5)
Virus-like particle 6 (4.4)
Virus-like particle+antigen presenting cell 2 (1.5)
Live-attenuated virus 2 (1.5)
Viral vector (non-replicating)+antigen presenting cell 1 (0.7)
Bacterial antigen-spore expression vector 1 (0.7)

COVID-19, coronavirus disease 2019.

Data as of December 3, 2021 (source:

Table 4.
Comparison of quality control tests for final products
United States (USP)
Europe (EDQM)

Korea (MFDS)
Japan (NIID)a)
Item Attribute Possible test methods
Identity Sequence confirmation DNA extraction & sequencing (USP 1125, 1126) restriction analysis (USP 1129, 1126) Immunochemical methods (EP 2.7.1), NAT (EP 2.6.21), LC (EP 2.2.29) Immunochemical methods. NAT, LC Suitable methods
Vector detection qPCR, ddPCR, RT-PCR (USP 1125, 1126, 1127), ELISA (USP 1103)
Purity Vector aggregates Light-scattering (USP 1430.2, 1430.3, 1430.5, 1430.6, 1430.7), SEC-MALS (USP 621, 1430.1) Light-scattering Light-scattering -
Potency Infectious vector titer Plaque assays (USP 111, 1235, 1237), CCID50, cell-based qPCR (USP 1032, 1033, 1034) Plaque assays or CCID50 assay by immunostaining, qPCR, flowcytometry/FACS, fluorescent focus assay Plaque assays or CCID50 assay by immunostaining, qPCR, flowcytometry, fluorescent focus assay Immunostaining
Transgene expression Western blot (USP 1104), ELISA (USP 1103), LC-MS (USP 621, 736, 1736), RP-HPLC (USP 621) Immunochemical assay (EP 2.7.1), biochemical assay, flow cytometry (EP 2.7.24) Immunochemical assay, biochemical assay, flow cytometry -
Quantity Virus particle (vector concentration) Light-scattering & DLS (USP 1430.2, 1430.6), CZE (USP 1053), qPCR (USP 1125, 1126, 1127) qPCR (EP 2.6.21) qPCR LC
Appearance Compendial test USP 1, 790 EP 2.7.1, 2.6.21, 2.2.29 Visual observation Criteria specified
pH Compendial test USP 791 EP 2.2.3 KP general test JP general test
Container content for injections (includes extractable volume) Compendial test USP 697 EP 2.9.17 KP general test -
Sterility Compendial test USP 71 EP 2.6.1 KP general test JP general test
Endotoxin Compendial test USP 85 EP 2.6.14 KP general test JP general test
Osmolality Compendial test USP 785 EP 2.2.35 KP general test -

USP, United States Pharmacopoeia; EDQM, European Medicines Quality Committee; MFDS, Ministry of Food and Drug Safety; NIID, National Institute of Infectious Diseases; EP, European Pharmacopoeia; NAT, nucleic acid test; LC, liquid chromatography; qPCR, quantitative polymerase chain reaction; ddPCR, droplet digital PCR; RT-PCR, reverse transcription PCR; ELISA, enzyme-linked immunosorbent assay; SEC, size exclusion chromatography; MALS, multi-angle light-scattering; CCID50, cell culture infectious dose 50%; FACS, fluorescence-activated cell sorting; MS, mass spectrometry; DLS, dynamic light-scattering; CZE, capillary zone electrophoresis; RP, reverse phase; HPLC, high-performance liquid chromatography; KP, The Korean Pharmacopoeia; JP, Japanese Pharmacopoeia; -, not applicable.

a) Chimpanzee adenoviral vector vaccine only.

Table 5.
National lot release test items and methods in the Republic of Korea
Test item Test methods
General Appearance Confirm color, shape formulation, etc. by visual observation
Container content for injections Compendial test such as KP general test 65
pH Compendial test such as KP general test 76
Product- specific Quantity Vector concentration (virus particles) such as qPCR, liquid chromatography, etc.
Identity Identification of vector including genetic insert such as liquid chromatography, qPCR and gel electrophoresis system, etc.
Potency Determination of transgene expression by qPCR, ELISA, immunostaining, etc.
Purity Determination of vector aggregation such as liquid chromatography, light-scattering tests
Safety Sterility Compendial test such as KP general test 12
Endotoxin Compendial test such as KP general test 40

KP, The Korean Pharmacopoeia; qPCR, quantitative polymerase chain reaction; ELISA, enzyme-linked immunosorbent assay.

Table 6.
Viral vector vaccine laboratory test items performed by the NRA/NCL
NRA/NCL EMA (OMCL) Australia (TGA) Korea (MFDS)
Test items Appearance, potency, identity (potency may serve as an identity test) Composition and strength, purity and integrity, endotoxin Appearance, pH, quantity, identity, potency, purity, sterility, endotoxin, container content for injection

NRA, National Regulatory Authority; NCL, National Control Laboratory; EMA, European Medicines Agency; OMCL, European Network of Official Medicines Control Laboratories; TGA, Therapeutic Goods Administration; MFDS, Ministry of Food and Drug Safety.

Table 7.
Content of the summary protocol for viral vector vaccines
Category Description
1. General a. Information about the product that has been applied for lot release
 1) Name of applicant, name of representative, and address
 2) Name of the preparation pursuant to the MRBP (MFDS Notification)
 3) Product name, lot number, manufacturing date, expiry date, period of usage, packaging unit, storage
 4) Amount that has been applied for national lot release
b. Summary on manufacturing information
 1) Lot number of the raw materials (master cell strains, working cell strains/virus strains), material (master cell line/virus strain, production cell line/virus strain), manufacturing date, etc.
 2) Bulk, lot number of the final bulk, manufacturing date and manufacturer
 3) Lot number of final product, manufacturing date, manufacturer, total amount of production, and bottling date
2. Raw materials With regard to the raw materials, testing items, methods, results, detailed information related to the manufacturing, etc. must be included. For cell strains and virus strains, information on the passage history, number of passages, etc. must be included
3. Bulk a. Information about half-finished products (intermediates) that are produced during the manufacturing of bulk, name, lot number, manufacturing date, manufacturer, storage conditions (temperature and container), period of storage, amount of production, etc.
b. Information about bulk, lot number, manufacturing date, manufacturer, storage conditions (temperature and container), period of storage, amount of production, major production methods, etc.
c. Information about quality control, information related to the testing items, methods, specifications, period, results, etc. of a test performed according to the quality control manual and approval items of a bulk and materials used for producing the bulk
4. Final bulk a. Information about the material used for producing the final bulk, corresponding material’s ingredient name, lot number, added amount, etc.
b. Information about the final bulk, lot number, manufacturing date, manufacturer, storage conditions (temperature and container), period of storage, amount of production, etc.
c. Information about quality control, testing items, methods, specifications, period, results, etc. of a test conducted according to the quality control manual and approval items of a final bulk
5. Final product a. Information about the drug product, lot number, manufacturer, specification of a container, filling amount, bottling date, manufacturing date, total amount of production, storage, expiration date (shelf life), etc.
b. Information about quality control, testing items, methods, specifications, period, results, etc. of a test conducted according to the quality control manual and approval items of a final product
c. For imported drug products, information that is recorded additionally by an importer, lot number, manufacturer, manufacturing date, date of customs clearance, imported amount, storage method, expiry date (shelf life) in addition to the testing items, methods, specifications, period, results, etc. of a test conducted by the importing party should be included.
d. If attached reconstitution solution is included, regarding information about manufacturer, lot number, manufacturing date, expiration date, specifications, and test results

MRBP, Minimum Requirements for Biological Products; MFDS, Ministry of Food and Drug Safety.

Figure & Data



    Citations to this article as recorded by  

      Related articles

      PHRP : Osong Public Health and Research Perspectives